Alpha 2.0
Login Register
» Authors » Richard Bryce

Richard Bryce

Explore the profile of Richard Bryce including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 38
Citations 1669
Followers 0
Related Specialties
Oncology
Health Services
Public Health
Top 10 Co-Authors
Sung-Bae Kim
Alshad S Lalani
Beverly Moy
Cristina Saura
Suzette Delaloge
Bin Yao
Kenichi Inoue
Ron Bose
Judith Bebchuk
Paul J Fleming
Published In
Clin Cancer Res
Breast Cancer Res Treat
Prostaglandins Leukot Essent Fatty Acids
Lancet Oncol
Prev Med Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
Chronic Cellulitis in the Unhoused: Case Study and Treatment Considerations
Klamen A, Bryce R, Martin S, Benchell Eisman E
J Prim Care Community Health . 2024 Jul; 15:21501319241249437. PMID: 39058513
This report seeks to discuss sequelae of chronic cellulitis that is commonly treated in the ambulatory setting, as exacerbated by the conditions of living outside. Further we hope to identify...
2.
SARS-CoV-2 inhibitory potential of fish oil-derived 2-pyrone compounds by acquiring linoleic acid binding site on the spike protein
Duragkar N, Chikhale R, Piechota M, Danta C, Gandhale P, Itankar P, et al.
Int J Biol Macromol . 2024 Jul; 275(Pt 1):133634. PMID: 38964690
Traditional medicines have reportedly treated SARS-CoV-2 infection. Substantial evidence shows that fish oil supplements promote human immune function, suggesting they may lessen susceptibility to SARS-CoV-2 infection and suppress viral replication...
3.
Getting the word out: Methods of learning about research and motivations for participation in a study focusing on a reproductive-aged Latina/x population
Sekula N, Plowden T, Waldo A, Bryce R, Castillo-Mackenzie M, Acosta S, et al.
J Clin Transl Sci . 2022 May; 6(1):e40. PMID: 35574152
Background: Although one of the fastest-growing populations in the USA, Latinx individuals remain underrepresented in research. In this study, we aimed to identify how Latina/Latinx participants of the Environment, Leiomyomas,...
4.
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Ma C, Luo J, Freedman R, Pluard T, Nangia J, Lu J, et al.
Clin Cancer Res . 2022 Jan; 28(7):1258-1267. PMID: 35046057
Purpose: HER2 mutations (HER2mut) induce endocrine resistance in estrogen receptor-positive (ER+) breast cancer. Patients And Methods: In this single-arm multi-cohort phase II trial, we evaluated the efficacy of neratinib plus...
5.
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with...
Dai M, Feng Y, Chen S, Masuda N, Yau T, Chen S, et al.
Breast Cancer Res Treat . 2021 Sep; 189(3):665-676. PMID: 34553296
Purpose: Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has demonstrated systemic efficacy and intracranial activity in various stages of HER2+breast cancer. NALA was a phase III randomized trial that assessed...
6.
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Saura C, Matito J, Oliveira M, Wildiers H, Brufksy A, Waters S, et al.
Clin Cancer Res . 2021 Aug; 27(21):5818-5827. PMID: 34380637
Purpose: Neratinib plus capecitabine (N+C) demonstrated significant progression-free survival (PFS) benefit in NALA (NCT01808573), a randomized phase III trial comparing N+C with lapatinib + capecitabine (L+C) in 621 patients with...
7.
A pilot randomized controlled trial of a fruit and vegetable prescription program at a federally qualified health center in low income uncontrolled diabetics
Bryce R, WolfsonBryce J, CohenBryce A, Milgrom N, Garcia D, Steele A, et al.
Prev Med Rep . 2021 Jun; 23:101410. PMID: 34150472
Eating a healthy diet is important for managing diabetes. Although there are high rates of diabetes in low-income urban areas, these patients often have limited access to fruits and vegetables....
8.
Immigration law enforcement, social support, and health for Latino immigrant families in Southeastern Michigan
Benavides Q, Doshi M, Valentin-Cortes M, Militzer M, Quinones S, Kraut R, et al.
Soc Sci Med . 2021 May; 280:114027. PMID: 34029864
Rationale: Social support is a key determinant of physical and mental health outcomes. Implementation of restrictive immigration policies in the U.S. under the Trump administration impacted the way mixed-status Latino...
9.
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
Hurvitz S, Saura C, Oliveira M, Trudeau M, Moy B, Delaloge S, et al.
Oncologist . 2021 May; 26(8):e1327-e1338. PMID: 34028126
Background: Neratinib has efficacy in central nervous system (CNS) metastases from HER2-positive metastatic breast cancer (MBC). We report outcomes among patients with CNS metastases at baseline from the phase III...
10.
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
Moy B, Oliveira M, Saura C, Gradishar W, Kim S, Brufsky A, et al.
Breast Cancer Res Treat . 2021 Apr; 188(2):449-458. PMID: 33909203
Purpose: To characterize health-related quality of life (HRQoL) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) from the NALA phase 3 study. Methods: In...